Zeleciment rostudirsen (z-rostudirsen)

Name: Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: Diagnosis
Published: 2026-09-14T15:39:06-04:00

Duchenne muscular dystrophy

Also known as DYNE-251

Manufacturer: Dyne Therapeutics
Regulatory submission: BLA submitted May 2026
Launch: Anticipated in the first quarter of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Diagnosis

2 evidence topics · 3 sources

Genetic patient selection

“confirmed DMD mutation in the dystrophin gene characterized by exon deletion amenable to exon 51 skipping.” (opens the source at this quote in a new tab)

Diagnostic delay in males without a family history of muscular dystrophy

“Time between noticing signs and diagnosis was about 2.5 years” (opens the source at this quote in a new tab)
“Average age at diagnosis was 5 years” (opens the source at this quote in a new tab)